These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9001409)

  • 1. Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome.
    Wijermans PW; Krulder JW; Huijgens PC; Neve P
    Leukemia; 1997 Jan; 11(1):1-5. PubMed ID: 9001409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome.
    Wijermans PW; Krulder JW; Huijgens PC; Neve P
    Leukemia; 1997 Mar; 11 Suppl 1():S19-23. PubMed ID: 9130687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.
    Lübbert M; Wijermans P; Kunzmann R; Verhoef G; Bosly A; Ravoet C; Andre M; Ferrant A
    Br J Haematol; 2001 Aug; 114(2):349-57. PubMed ID: 11529854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.
    Wijermans P; Lübbert M; Verhoef G; Bosly A; Ravoet C; Andre M; Ferrant A
    J Clin Oncol; 2000 Mar; 18(5):956-62. PubMed ID: 10694544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients.
    Wijermans PW; Lübbert M; Verhoef G; Klimek V; Bosly A
    Ann Hematol; 2005 Dec; 84 Suppl 1():9-17. PubMed ID: 16211386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends.
    Pinto A; Zagonel V
    Leukemia; 1993 May; 7 Suppl 1():51-60. PubMed ID: 7683358
    [No Abstract]   [Full Text] [Related]  

  • 8. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
    Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
    Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
    Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
    Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Beran M; Estey E; O'Brien SM; Giles FJ; Koller CA; Kornblau S; Keating M; Kantarjian HM
    Leuk Lymphoma; 1998 Nov; 31(5-6):521-31. PubMed ID: 9922042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes.
    Zagonel V; Lo Re G; Marotta G; Babare R; Sardeo G; Gattei V; De Angelis V; Monfardini S; Pinto A
    Leukemia; 1993 May; 7 Suppl 1():30-5. PubMed ID: 7683354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
    Hackanson B; Robbel C; Wijermans P; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
    Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
    J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study.
    Salim O; Toptas T; Avsar E; Yucel OK; Ozturk E; Ferhanoglu B; Geduk A; Mehtap O; Tombak A; Tiftik EN; Deveci B; Kurtoglu E; Kara O; Atagunduz IK; Tuglular TF; Undar L
    Leuk Res; 2016 Jun; 45():82-9. PubMed ID: 27107658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
    Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
    Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
    Wang M; Han HH; Guo R; Liu YF; Jiang ZX; Sun H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1482-1486. PubMed ID: 29070129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.
    Iastrebner M; Jang JH; Nucifora E; Kim K; Sackmann F; Kim DH; Orlando S; Jung CW; Basquiera A; Klein G; Santini F; Bernard HI; Korin J; Taborda G
    Leuk Lymphoma; 2010 Dec; 51(12):2250-7. PubMed ID: 20929328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
    Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
    Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
    Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
    Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
    Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.